

If the 19th century was the century of chemistry and the 20th the century of physics, we believe the 21st will be the century of biology.

Revolutionary advances across multiple fields including computer science, artificial intelligence, big data analytics, automation, chemistry, biology, and engineering are creating previously unimaginable new opportunities to re-engineer biological systems in ways that will revolutionize healthcare, agriculture, manufacturing, energy production, consumer services, and data storage.

The WisdomTree BioRevolution Fund (WDNA) seeks to provide targeted exposure to companies that have the potential to be significantly transformed by advancements in genetics and biotechnology. WDNA seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (WTDNA), a basket of companies that may be uniquely positioned to seize the opportunity at the intersection of biology and technology.

The WisdomTree BioRevolution Index – Created with Input from Dr. Jamie Metzl

To construct the WisdomTree BioRevolution Index, we leverage data from leading technology futurist Dr. Jamie Metzl as a third-party consultant. Well recognized as a thought leader on the biology revolution, Dr. Metz authored *Hacking Darwin: Genetic Engineering and the Future of Humanity* and he serves as a member of the World Health Organization's expert committee on human genome editing.

WisdomTree and Dr. Metz share the view that the application of genetics and biotechnology will extend far beyond healthcare. In our shared view, the biology revolution is creating a historic investment opportunity equivalent to the industrial and internet revolutions.


Considering proprietary data from Dr. Metz, the WisdomTree BioRevolution Index identifies the key sectors and industry verticals that are expected to be most significantly transformed by advances in biological science and technology, as well as the companies that WisdomTree believes are most representative of this wave of innovation.

Human Health	Agriculture and Food	Materials, Chemicals, & Energy	Biological Machines & Interfaces
<p><i>The application of genetic technologies to prevent and treat disease will lead to significant enhancements to human health, well-being, and longevity.</i></p> <ul style="list-style-type: none">• Diagnostics & Surveillance• Precision Health/Gene Therapies• Regenerative Medicine/Stem Cell• Vaccines	<p><i>The genetics and biotechnology revolutions will increasingly transform agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding our growing population.</i></p> <ul style="list-style-type: none">• Precision Agriculture• Plant-Based Meats• Cellular Agriculture	<p><i>Biological reengineering will be used to produce an increasing percentage of the physical inputs needed for manufacturing.</i></p> <ul style="list-style-type: none">• Synthetic Manufacturing and Precision Fermentation• Biofuels	<p><i>DNA has approximately one million times greater storage capacity than hard-disk storage.</i></p> <ul style="list-style-type: none">• DNA Data Storage• Biological Computers• Brain-Machine Interfaces

Source: WisdomTree, Jamie Metzl

Our Differentiated BioRevolution Investment Approach

The WisdomTree BioRevolution Index is constructed to track exposure to the BioRevolution megatrend. Our screening process merges both qualitative and quantitative evaluations of eligible stocks to identify a portfolio of best-in-class companies working at the forefront of these biological breakthroughs.



Source: WisdomTree, Jamie Metzl. The present summary is not exhaustive. Please refer to the Index methodology for further details. You cannot invest directly in an index.

1. Developed world stock exchanges in the U.S., Europe, Tokyo Stock Exchange or on stock exchanges in Australia, Israel, Hong Kong, Singapore, or Canada.

2. The Index is overseen by the WisdomTree BioRevolution Index Committee (the “Committee”), a standing index committee of WisdomTree Investments, Inc. (“WisdomTree”), ticker WETF. The Committee will be composed of not less than 3 members. The Committee is responsible for making broad decisions with respect to the implementation, ongoing management, operation and administration of the Index. The primary function of the Committee is to make sure the Index rules are implemented correctly and comprehensively, provided that the published Index composition shall be as determined by the Committee.

A Broad Impact, Beyond Healthcare, with Potential to Transform our Economies and Lives

The genetics and biotechnology revolutions are most often associated with healthcare because many of the most high-profile preliminary applications have been healthcare related. The quantity and quality of these applications may increase significantly over the coming years as our healthcare systems transition from generalized medicine based on population averages to personalized, or precision, healthcare based on each person’s individual biology.


Powerful gene therapies treating some cancers and other diseases are only early examples of what could be increasingly possible as these technologies help us live healthier, longer, and more robust lives. Our global experience of the COVID-19 pandemic has also demonstrated the critical importance of our new biotechnology capacities for pathogen surveillance, disease treatment, and vaccine development.

But the application of the genetics and biotechnology revolutions will extend far beyond healthcare.

Agriculture is but one example. Knowing nothing about genetics, our ancestors were able to domesticate previously wild plants and animals through selective breeding. Today, these new technologies we believe will supercharge the selective breeding process to accomplish in months or short years what previously might have taken centuries or millennia. Pest resistance, yield, and variety can be enhanced significantly for staple crops, which can also be engineered to significantly increase photosynthesis to slow climate change. Domesticated animals can be engineered to increase disease resistance, productivity, and product quality through marker assisted selective breeding targeting specific desired outcomes.

The sourcing of industrial inputs for manufacturing is another area ripe for transformation. As the human population grows toward an estimated ten billion people by mid-century, it is clear that current resource extraction models will not be sustainable. The tools of the genetics and biotechnology revolutions, however, are making it possible to create materials at scale by manipulating genetic code rather than extracting them from nature. Instead of making plastic from petroleum and fragrances from flowers, for example, we are able to produce both through the genetic engineering of yeast and other microbes.

The WisdomTree BioRevolution Fund aims to have exposure across the BioRevolution impact chain. Today, WDNA holds approximately 80% of its weight in the Human Health sector. Over time, we expect the fund to have increased exposure to sectors like Agriculture & Food and Materials, Chemicals, & Energy. The shift in exposure is expected because the multiple technologies underpinning the BioRevolution are connected and constantly reinforcing advancements across interdisciplinary fields.



Source: WisdomTree, Jamie Metzl as of 6/30/2021. Prediction and Prevention within the Human Health sector is currently a 0.4% weight. Synthetic Manufacturing and Precision Fermentation within the Agriculture & Food sector is currently a 0.9% weight. Companies that have exposure to multiple sectors or subsectors have their weight divided evenly across relevant exposures. Weights subject to change. You cannot invest directly in an index.

WisdomTree BioRevolution Index – Company Examples				
Sector	SubSector	Company	Weight	Business Description
Human Health	Precision Health/Gene Therapies	Moderna	0.7%	Develops transformative medicines based on messenger ribonucleic acid (mRNA)
	Vaccines	Regeneron	0.9%	Discovery, invention, development, manufacture, and commercialization of medicines
	Healthy Aging	Unity Biotechnology	0.7%	Research and development of therapeutics to slow, halt, or reverse diseases of aging
	Diagnostics and Surveillance	10X Genomics	0.8%	Life science tools and integrated systems for large-scale analysis of genetic variation and function
	Assisted Reproduction/Fertility	Natera	0.8%	Discovery, development, and commercialization of genetic testing services
	Regenerative Medicine/Stem Cell	Athersys	0.7%	Stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions
	Prediction and Prevention	Invitae	0.8%	Comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases
Agriculture & Food	Precision Agriculture	Bayer	0.8%	Portfolio of high-value seeds, improved plant traits, innovative chemical and biological crop protection products
	Cellular Agriculture	Precision BioSciences	1.0%	Proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies
	Plant-Based Meats	Beyond Meat, Inc.	1.0%	Provision of plant-based meat
Materials, Chemicals, & Energy	Biofuels	Verbio	0.8%	Production and distribution of biofuels.
	Synthetic Manufacturing and Precision Fermentation	Codexis	0.8%	Enzyme engineering company, which engages in the development and sale of therapeutics

Source: WisdomTree, Jamie Metzl, FactSet as of 6/30/2021. You cannot invest directly in an index.

Gaining Exposure to the Far-Reaching Impact of the Biology Revolution

The revolution in our ability to read, understand, write, and hack DNA, the genetic code of all life, will touch most aspects of how we live.

Although the general direction and accelerating pace of this revolution are nearly certain, the time horizons for how each specific application will play out will vary. For this reason, we believe the diverse portfolio of companies captured in WDNA is the best way for investors to gain exposure to the biology revolution that we expect to fundamentally transform our world and lives over the coming years.

Quick Facts ¹	
Ticker	WDNA
Exchange	CBOE
Expense Ratio	0.45%
Structure	Open-end ETF
Exposure	Companies that will be significantly transformed by advancements in genetics and biotechnology over the medium- to long-term.
Number of Holdings	116
Rebalancing	Semi-annually in April and October

At WisdomTree, we do things differently. We build our ETFs with proprietary methodologies, smart structures and uncommon access to provide investors with the potential for income, performance, diversification and more.

For more information on WDNA, contact your WisdomTree representative or visit WisdomTree.com.

¹ As of 6/30/2021.

Statements concerning trends in the fields, industries and sectors discussed are based on current conditions, which will fluctuate. This material represents an assessment of trends discussed at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This material should not be relied upon as research or investment advice regarding any security in particular. The user of this information assumes the entire risk of any use made of the information provided herein.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Fund before investing. To obtain a prospectus containing this and other important information, call 866.909.9473 or visit WisdomTree.com. Read the prospectus carefully before you invest.

There are risks associated with investing, including possible loss of principal. The Fund invests in BioRevolution companies, which are companies significantly transformed by advancements in genetics and biotechnology. BioRevolution companies face intense competition and potentially rapid product obsolescence. These companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations or policies. Additionally, BioRevolution companies may be subject to risks associated with genetic analysis. The Fund invests in the securities included in, or representative of, its Index regardless of their investment merit and the Fund does not attempt to outperform its Index or take defensive positions in declining markets. The composition of the Index is governed by an Index Committee and the Index may not perform as intended. Please read the Fund's prospectus for specific details regarding the Fund's risk profile.

References to specific securities and their issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities.

WisdomTree Funds are distributed by Foreside Fund Services, LLC, in the U.S. only. Foreside Fund Services, LLC, is not affiliated with the entities mentioned.

© 2021 WisdomTree Investments, Inc. "WisdomTree" is a registered mark of WisdomTree Investments, Inc.

WTGM-5117